What You Should Know About the Gene Therapy That Restored Boy's Sight

Written by Partha Nandi, MD, FACP

A team of doctors in London did something that had never been done before. They took four young children, all born blind from a rare genetic condition, gave each one a single injection into the back of one eye, and watched usable vision appear where there had been almost none.

This is gene therapy for inherited blindness, and it caught my eye for a simple reason. These were toddlers whose retinas were already dying, born with a form of blindness that had no treatment at all. Within a few weeks of the injection, some of them were reaching for toys, turning toward light, and starting to make out faces.

I want to walk you through the real study behind the headlines, because it’s both more impressive and more careful than the viral version. This is early science, tested in a small number of children, and it’s still experimental. But it’s a real look at where medicine is going.

Dr. Nandi’s Bottom Line

A first-of-its-kind trial gave four children with a rare inherited blindness one gene-therapy injection, and all four gained real, usable vision. The results are early, and the therapy is still experimental and specific to one rare genetic condition. For almost everyone else, the lesson is simpler: early eye exams, genetic testing when eye disease runs in the family, and protecting the sight you already have.

Meet Jace

Jace’s parents, Brendan and DJ, first noticed something was off when he was just a few weeks old. At an age when most babies begin locking eyes with their caregivers, Jace’s gaze drifted. He didn’t track movement. He didn’t react to facial expressions. For new parents, these missing signs weren’t just unsettling—they were a red flag.

What followed was nearly a year of searching for answers. Multiple doctor visits. Tests. Referrals. Second opinions. Eventually, they got a diagnosis: Jace had Leber Congenital Amaurosis (LCA), one of the most severe inherited forms of childhood blindness. His specific case was tied to a rare mutation in the AIPL1 gene—critical for the survival of photoreceptors, the light-sensing cells in the retina.

The prognosis wasn’t good. Children with this mutation lose vision rapidly, often leaving them with only minimal light perception, which usually fades completely over time. At the time, there was no approved treatment. No roadmap. Just the reality of raising a child who would grow up in a world without sight.

For Brendan and DJ, the diagnosis was both a shock and, strangely, a relief. They finally had a name for what was happening—but no clear way forward. Then came a question no parent wants to face: What do you do when there’s nothing you can do?

A Last-Ditch Option

Jace’s parents didn’t stop searching after the diagnosis. In the absence of a treatment, they looked for possibilities—anything that could help. By chance, while attending a medical conference about inherited eye disorders, they heard about a clinical trial preparing to launch in London.

The study was designed specifically for children with Jace’s exact mutation in the AIPL1 gene. Researchers at Moorfields Eye Hospital and University College London were testing a gene therapy that had never been used in humans with this condition. The goal: deliver healthy copies of the faulty gene directly into the retina and see if any function could be restored.

The therapy wasn’t approved. It wasn’t widely available. But it was being offered under a compassionate use license for a small group of children with no other options.

Jace was just two years old when his family was told he qualified for the trial. The decision wasn’t easy. The procedure was experimental. The outcomes were uncertain. But doing nothing guaranteed continued vision loss.

For Brendan and DJ, the choice came down to one simple fact: this was the only shot. They traveled from Connecticut to London, hoping the therapy might give their son something he’d never had—a chance to see.

The Procedure

At Moorfields Eye Hospital in London, Jace underwent surgery to receive the gene therapy. The process was precise and highly specialized, but conceptually simple: replace what’s missing.

Surgeons used keyhole surgery to inject healthy copies of the AIPL1 gene directly into the retina of one eye. The gene was packaged inside a harmless viral vector—engineered specifically to enter retinal cells and deliver its genetic payload without causing illness. Once inside the cells, the working gene would ideally take over the function that Jace’s faulty gene couldn’t perform: keeping photoreceptors alive and functional.

The operation took about an hour. There were no dramatic incisions—just four small entry points. The other eye was intentionally left untreated. This was standard protocol in early trials to minimize risk. If something went wrong, at least one eye would remain untouched.

The science behind the therapy was solid, but this was still uncharted territory for this specific mutation. Doctors made no promises. The goal wasn’t full restoration of sight. It was about preserving what little retinal function remained—and, if possible, bringing some vision back.

Now, all they could do was wait.

Early Signs of Success

It didn’t take long for Brendan and DJ to notice something had changed.

Just weeks after surgery, sunlight streamed into their home one morning—and Jace squinted. That might sound small, but for a child who had never reacted to light, it was the first clear sign his treated eye was starting to work.

Before the procedure, Jace couldn’t track objects, even when held right in front of him. Afterward, he began reaching for toys on the floor. He reacted to movement. He started exploring his environment in new ways—visually.

At school, teachers noticed a shift too. Jace was swiping phones from pockets, responding to visual cues, and engaging with the world in ways he hadn’t before. At home, he picked up crayons. Scribbles became lines. Lines became letters.

Clinical tests confirmed what everyone was seeing. The treated eye showed improved visual responses and a more preserved retinal structure. The untreated eye continued to decline, as expected. The contrast between the two was stark—and powerful.

The improvements weren’t dramatic all at once. But they were clear, steady, and—most importantly—real.

The Science Behind the Breakthrough

At the core of this therapy is a single gene: AIPL1. In healthy eyes, this gene supports the survival and function of photoreceptors—the light-sensitive cells in the retina that convert light into electrical signals for the brain. When AIPL1 is mutated, those cells begin to fail almost immediately after birth. Vision rapidly deteriorates, often to complete blindness within a few years.

The therapy Jace and the other children received was designed to address that failure at its source. Scientists used a viral vector—a modified, harmless virus—as a delivery tool. It carried healthy copies of the AIPL1 gene and delivered them directly into the retina through a minimally invasive surgical procedure.

Once inside the cells, the replacement gene began producing the protein that had been missing from birth. The goal was to halt the degeneration of photoreceptors and, where possible, re-activate their function.

Timing was critical. The children were treated between ages one and three—early enough that some retinal cells were still alive and potentially able to respond. That’s why this trial focused on very young children. Waiting longer could have meant missing the window where vision could still be saved.

Follow-up tests showed that the treated eyes had stronger visual signals, better retinal structure, and improved function compared to the untreated eyes. These weren’t abstract data points. They lined up with what families saw at home—children reacting to light, finding toys, drawing pictures, and walking more confidently.

This wasn’t just proof of concept. It was proof of possibility—delivered at the right time, in the right way, with measurable results.

What This Means for the Future

The results of this early trial go beyond the four children involved. They open the door to a new approach for treating genetic blindness—especially when caught and addressed early.

Until now, there was no treatment for AIPL1-related LCA. This therapy shows that vision loss from even the most aggressive forms of inherited blindness can be slowed, and in some cases, partially reversed—if intervention happens early enough.

This study also reinforces something already seen with other gene therapies. In 2020, Luxturna—a gene therapy targeting a different mutation (RPE65)—was approved in the U.S. and U.K. It showed that gene replacement could restore functional vision in patients who were previously considered untreatable.

What’s different here is how early the intervention happened—and how effective it was in such young patients. That could shift the standard for when and how these therapies are offered. Researchers now have a clear goal: catch the disease earlier, intervene faster, and preserve vision before it’s lost for good.

The team behind this trial is continuing to follow the children long-term and exploring ways to make the treatment more widely available. That includes working toward regulatory approval and scaling production so that children outside of clinical trials can eventually benefit.

For families facing genetic blindness, this trial offers more than hope—it offers evidence. And that’s what changes medicine.

My Personal RX on Protecting the Vision You Have

A breakthrough like this is thrilling to watch, but most of us will never need a gene therapy for our eyes. What we will need is vision that lasts. The good news is that the retina responds to the same things the rest of your body does: steady blood sugar, good circulation, protection from damage, and a reliable supply of the nutrients it runs on.

None of these tips will rewrite your genes. What they will do is give your eyes their best shot at staying sharp for the long haul, and support the brain-and-eye system those photoreceptors belong to. Here’s what I’d put on your list.

Keep your eye exams on schedule. A dilated eye exam can pick up retinal, macular, and pressure changes long before you notice a thing. If you’re over 40, have diabetes, or have a family history of eye disease, don’t stretch the gaps between visits.
Eat for your macula. Leafy greens like spinach and kale, orange and yellow vegetables, and eggs deliver lutein and zeaxanthin, the pigments that gather in the macula and help filter harsh light. Color on the plate is color in the retina.
Give your retinas the fats they’re built from. DHA, a key omega-3 fat, is a structural building block of the retina and the vision centers of the brain. If you’re not eating fatty fish a few times a week, a clean omega-3 supplement is an easy way to keep those levels where they should be, for your eyes and your heart alike.
Protect against UV every day. Wear sunglasses that block both UVA and UVB, even in winter and on cloudy days. Ultraviolet light adds up over a lifetime and raises the risk of cataracts and retinal damage.
Treat your eyes, gut, and brain as one connected system. Those photoreceptors are nervous-system cells, and they rely on good digestion and nutrient absorption to get what they need. A combined approach like the Gut Brain Reset Bundle, which pairs gut and cognitive support with targeted eye support, is a simple way to cover that whole axis at once.
Keep blood sugar steady. High blood sugar quietly damages the tiny vessels that feed the retina, which is why diabetes is a leading cause of vision loss. Steady glucose protects your sight as much as it protects the rest of you.
Mind your blood pressure. The retina is full of delicate blood vessels, and high pressure wears them down over time. Keeping your numbers in range is eye care you can’t see happening.
Don’t smoke, and go easy on alcohol. Smoking is one of the biggest controllable risks for macular degeneration and cataracts. If you smoke, quitting is one of the best things you can do for your eyes and your whole body.
Give your eyes real screen breaks. Every 20 minutes, look at something about 20 feet away for 20 seconds. It won’t change your genes, but it eases the strain and dryness that come with long hours on a screen.
Know your family’s eye history. If inherited eye disease runs in your family, ask your doctor about genetic testing and early eye exams for your kids. As this trial showed, an early diagnosis is what opens the door to new options when they exist.

When to See a Doctor

Most vision changes are ordinary and manageable, but a few signs are worth a prompt professional look rather than a wait-and-see. Check in with an eye doctor, or a pediatrician for a child, if you notice any of these.

In a baby or young child: not making eye contact, not following faces or objects by a few months of age, eyes that wander or move in a jerky, repetitive way, or constant eye poking and pressing.
Sudden vision loss, or a sudden burst of new floaters or flashes of light, in one or both eyes.
A curtain or shadow moving across your field of vision.
New, lasting blurring, double vision, or distortion where straight lines look wavy.
Eye pain, redness that won’t settle, or vision changes alongside a severe headache.
A slow loss of side or central vision you’ve been explaining away.

For infants especially, trust your instincts. The parents in this story noticed something early, and that early attention is part of what gave their children options later.

References:

Michaelides, M., et al. (2025). Gene therapy in children with AIPL1-associated severe retinal dystrophy: An open-label, first-in-human interventional study. The Lancet, 405, 648. https://doi.org/10.1016/S0140-6736(24)02812-5
University College London. (2025, February 20). Genetic therapy gives infants life-changing improvements in sight[Press release]. EurekAlert! https://www.eurekalert.org/news-releases/1074295
MedlinePlus Genetics. (n.d.). Leber congenital amaurosis. U.S. National Library of Medicine, National Institutes of Health. Retrieved November 9, 2026, from https://medlineplus.gov/genetics/condition/leber-congenital-amaurosis/
U.S. Food and Drug Administration. (2017, December 19). FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss [Press release]. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss
Restoring sight: The journey of AIPL1 from discovery to therapy. (n.d.). PubMed Central. Retrieved November 9, 2026, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12733016/
MeiraGTx. (n.d.). AIPL1-associated retinal dystrophy (Leber congenital amaurosis 4) [Program page]. Retrieved November 9, 2026, from https://meiragtx.com/programs-pipeline/aipl1-retinal-dystrophy/

Frequently Asked Questions

Can gene therapy cure blindness?

It depends on the cause. For a few specific inherited conditions tied to a single known gene, like the AIPL1 and RPE65 forms of retinal disease, gene therapy has restored meaningful vision in trials, and for RPE65 it’s an approved treatment. It isn’t a general cure for blindness, and it doesn’t help the common age-related causes like macular degeneration or glaucoma. The approach only works when a specific faulty gene can be identified and replaced, and when there are still living retinal cells to rescue.

Is this AIPL1 gene therapy available now?

Not as a standard, approved treatment yet. It’s been given to a small number of children under special regulatory licenses, and the results have been strong enough that its developer and a major drugmaker are now working with UK and US regulators toward approval. For now it stays experimental and limited to this one rare condition.

What is Leber congenital amaurosis?

LCA is a group of rare inherited eye disorders that cause severe vision loss from birth or early infancy. There are at least 20 genetic types, each tied to a different gene. The AIPL1 type, known as LCA4, is among the most severe, with vision loss that begins very early. Early signs can include not tracking objects, wandering or jerky eye movements, and eye poking.

How can I protect my own vision?

The everyday basics do most of the work: get regular eye exams, don’t smoke, keep blood sugar and blood pressure in check, wear UV-blocking sunglasses, and eat a diet rich in leafy greens, colorful produce, and omega-3s. If inherited eye disease runs in your family, ask your doctor about genetic testing and early eye exams for your children.